Company Active LTD

Company profile

Oxford Target Therapeutics Limited

Oxford Target Therapeutics New

Oxford Target Therapeutics Limited is a UK company with status active founded in 2022 based in South East England.

CRN
13886983
Founded
2022
Age
4

Overview

Legal name
OXFORD TARGET THERAPEUTICS LIMITED
Region
South East England
Registered address
BIOINNOVATION HUB, TONGE BUILDING OXFORD BROOKES UNIVERSITY
GIPSY LANE, HEADINGTON CAMPUS
OXFORD
OXFORDSHIRE
UNITED KINGDOM
OX3 0BP
Insolvency history
No

Latest accounts

Financial period: 1 Aug 2024 to 31 Jul 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
0

Company events

Reference milestones and recent Companies House filing stream events.

8 events
20 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Apr
2027

Accounts due

Accounts Due

Next accounts due date

06 May
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jul
2025

Accounts filed

Accounts

Last accounts made up date

05 Nov
2024

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzQ0MjAwODgzOGFkaXF6a2N4

Published 05 Nov 2024 08:57

05 Nov
2024

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzQ0MjAwNzc5MmFkaXF6a2N4

Published 05 Nov 2024 08:43

05 Nov
2024

Cessation Of A Person With Significant Control

Persons-with-significant-control

PSC07 | Transaction MzQ0MjAwNzYzNmFkaXF6a2N4

Published 05 Nov 2024 08:41

02 Feb
2022

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
0 years

Projects

2022 Collaborative R&D Lead participant

Oxford Target Therapeutics: Innovative therapy to halt proliferation of high mortality cancer

1 Sep 2022 to 31 Aug 2023

Awarded
£296,532
Total cost £296,532

Our technology addresses an important unmet medical need of global proportions. Namely, the treatment of a highly aggressive form of breast tumours, triple negative breast cancer, for which current treatment options are ineffective. This is reflected in the high mortality of the disease in the UK and elsewhere. As a result of more than nearly two decades ...

Product types

Collaborative R&D